News | Heart Failure | July 14, 2017

Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients

JACC report features Vectorious Medical Technologies’ digital wireless sensory implant for measuring pressures in the heart

Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients

July 14, 2017 — A review appearing in the July 18 issue of the Journal of the American College of Cardiology (JACC) discusses current and next-generation implantable hemodynamic monitors. The review particularly examines new approaches focused on the direct measurement of left atrial pressure (LAP), seeking to expand the use of pressure-guided congestive heart failure (CHF) management.

The report highlights Vectorious Medical Technologies, an Israeli company developing the world’s first digital wireless sensory implant for measuring LAP (currently available CardioMEMS technology is analog and measures pressure in the pulmonary artery [PAP]). Patients with CHF suffer from repeated admissions to the hospital due to fluid overload, typically presenting with edema of the legs and congestion of the lungs. The conventional approach of monitoring symptoms and measuring daily weights and a “wait and see” attitude, is the basis for the huge unmet need of recurrent hospital admissions, because these methods appear late and are unreliable signs of disease progression. This is also the main driver of the huge cost of this chronic medical condition, more than $30 billion a year, in the United States alone, according to background contained in the review.

“Intracardiac and PAP-guided management has become a focus of hospitalization reduction in CHF,” wrote William T. Abraham, M.D., and Leor Perl, M.D. Abraham is from the Departments of Medicine, Physiology and Cell Biology, Division of Cardiovascular Medicine, and the Davis Heart & Lung Research Institute, The Ohio State University, Columbus, Ohio. Perl is in the Cardiology Department, Rabin Medical Center, Petah Tikva, Israel; on the Sackler Faculty of Medicine, Tel Aviv University; and in the Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, Calif.

LAP, rather than PAP, is a direct reflection of left ventricular filling pressure — which is the primary pressure target for CHF management. Therefore, its direct measurement may provide more clinical information than PAP, according to the authors.

In the JACC review, Abraham and Perl say that CHF outcomes with CardioMEMS PAP technology have been encouraging. They write that, additional, more technologically-advanced, implantable hemodynamic monitoring systems are in development, and newer approaches to the use of this data (such as a physician-directed, patient self-management approach) may yet again revolutionize the management of patients with HF.

Both Abraham and Perl have received consulting fees from Vectorious. Perl is also the medical director.

Watch a VIDEO discussion with Abraham on several new technologies to treat HF and reduce heart failure readmissions from TCT 2016.

Read the article "Reducing Heart Failure Readmissions."

For more information: www.vectoriousmedtech.com

Related Content

Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

News | Heart Failure | March 12, 2019
V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief...
EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Overlay Init